c-Met Targeting Peptide Composition for Solubility and Affinity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing peptides targeting c-Met suffer from poor water solubility and limited affinity, hindering their clinical application in cancer therapy and diagnosis.
Innovation Solution
Development of peptides with improved water solubility and affinity to c-Met, formulated as specific sequences and derivatives, which can be conjugated with drugs for targeted delivery to cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing peptides targeting c-Met are used, then they can bind to c-Met protein, but they exhibit poor water solubility and limited affinity
Solution Approach 1:
The patent modifies the peptide structure by changing amino acid sequences and introducing specific chemical modifications (such as N-terminal acetylation, C-terminal amide, and side-chain modifications) to improve both water solubility and binding affinity simultaneously. This resolves the contradiction by optimizing molecular parameters rather than accepting the trade-off between solubility and affinity.
Solution Approach 2:
The patent creates composite peptide structures by combining hydrophilic and hydrophobic amino acid residues in specific arrangements, and by conjugating peptides with drugs or imaging agents. This composite approach allows the peptide to maintain both good water solubility and high binding affinity to c-Met.
2Ease of manufacture
If existing peptides targeting c-Met are used, then they can be synthesized, but they require improved affinity and solubility for clinical application
Solution Approach 1:
The patent optimizes peptide parameters including molecular weight, charge distribution, and hydrophilicity-hydrophobicity balance to achieve both ease of synthesis and high clinical efficacy. The modified sequences maintain simplicity for synthesis while dramatically improving binding affinity and solubility for therapeutic use.
3Object-affected harmful factors
If targeted drugs are used to treat cancer, then they can reduce damage to normal tissues, but existing c-Met targeting peptides have limited effectiveness due to poor solubility and affinity
Solution Approach 1:
By optimizing the peptide's physical-chemical parameters (solubility, stability, binding affinity), the patent ensures that the targeted drug can effectively reach and bind to c-Met on cancer cells, thereby achieving both reduced damage to normal tissues and high therapeutic efficacy.
Data Source
Figure 1~2A
Figure 2A
Figure 2B
AI summary
A peptide targeting c-Met, derivatives thereof, a pharmaceutical composition and drug-peptide conjugate comprising the peptide or the derivatives thereof, and the use of same in the detection, prevention or treatment of diseases (e.g., cancers). In addition, the peptide or the derivatives thereof can increase the water solubility of a drug.